By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval Of Opdivo (Nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer 4/24/2017 7:47:48 AM
Bristol-Myers Squibb (BMY)'s NASH Candidate Hits Main Goals In Mid-Stage Study 4/24/2017 7:25:34 AM
Bristol-Myers Squibb (BMY) And Nordic Bioscience A/S Announce Collaboration For Fibrosis Biomarker Technology 4/17/2017 9:05:01 AM
Bristol-Myers Squibb (BMY) Inks Two Separate Pacts With Biogen (BIIB) and Roche (RHHBY) For a Total of Up to $1.1B 4/13/2017 6:11:20 AM
Bristol-Myers Squibb (BMY) And Apexigen Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With APX005M In Advanced Solid Tumors 4/11/2017 6:17:27 AM
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC (AZN), Bristol-Myers Squibb (BMY) Drugs 4/10/2017 5:45:15 AM
FDA Accepts For Priority Review Bristol-Myers Squibb (BMY)’s Application For Opdivo (Nivolumab) In Previously Treated Dmmr Or MSI-H Metastatic Colorectal Cancer 4/5/2017 8:19:58 AM
Bristol-Myers Squibb (BMY) Wants More Kentuckians To Participate In Clinical Trials 4/4/2017 8:48:53 AM
Bristol-Myers Squibb (BMY)'s Next Big Bet After Opdivo Failure—IDOs 4/4/2017 7:08:00 AM
Bristol-Myers Squibb (BMY) And Incyte (INCY) To Advance The Combination Of Opdivo (Nivolumab) And Epacadostat Into First-Line Registrational Trials 4/3/2017 11:40:57 AM
12345678910...
//-->